The usability of search within IRT is enhanced

NEWS
Press-Release
Software
April 6, 2023

[Limassol – 06.04.2023] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.6.2. IRT update focuses on usability and efficiency of search for information on the platform. Previously, the content was adapted for QSP projects in Oncology development (IRT Onco version).

IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system. Initially, IRT is based on two main components. On the one hand, it is a fully-fledged database including a wide variety of features covering the immune system. On the other hand, it comprises Navigator that provides intuitive interface to interact with IRT Database. Thus, a modeler can apply calibrated sub-models exported from IRT as building blocks to simplify the model development process.

IRT is a part of InSysBio’s QSP software infrastructure being under constant upgrade. The users’ convenience is now enhanced by the new annotation style. The text that contains detailed information on parameters is available directly in the right panel. Each parameter now has its own personal tag that allows to find a detailed description of the value source. 

The identifications types were redefined:

  • Calculated. The parameters are calculated directly from in vitro experimental data with derived formulas.
  • Fitted. The supplementary models were developed for in vitro or in vivo experiment description. The parameters’ values were fitted against the data from the described experiment. The supplementary models’ description and additional information are attached to the parameters’ annotations.
  • Taken. The parameters were taken directly from the open source.
  • Arbitrary. These parameters are different for each specific model.
  • Assumed. The parameter’s value is assumed. The reasoning of an assumption is described in the annotation file attached to the parameter value.
  • Not_identified. This parameter was not identified in the current version of the database.

The description of the calculated parameters contains a direct link to the article about an in vitro experiment. Formulas used in parameter calculation may be found in the supplementary annotation files. The description of the fitted parameters now includes files that cover the fitting process and links to the open-source data. Additionally, the display of values has also been modified. They have been shortened and rounded for the ease of use. 

Veronika Musatova, Head of IRT development team, comments on the new version, “This update will help users to quickly and easily find the links to the data used for parameters identification. Moreover, files of the models exported from IRT will also include this information after the update”.

Furthermore, the demo version of IRT has been also updated. Two sub models are now available in the demo version: IL6 and Neutrophils. The information on parameters is displayed in the same way as in the full IRT version. 

To learn the full content of Immune Response Template, please visit irt.insysbio.com.

To get demo access to IRT, please click “sign in” or “user account” on the irt.insysbio.com.

To get more information on any tool or leave your feedback, please feel free to contact us: support@insysbio.com

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com